Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | REGN5093 |
| Synonyms | |
| Therapy Description |
REGN5093 is a bispecific MET antibody that targets two different epitopes on MET, potentially leading to degradation of MET and decreased tumor cell growth (PMID: 37059804, NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| REGN5093 | REGN-5093|REGN 5093|davutamig | MET Antibody 38 | REGN5093 is a bispecific MET antibody that targets two different epitopes on MET, potentially leading to degradation of MET and decreased tumor cell growth (PMID: 37059804, NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04077099 | Phase Ib/II | REGN5093 | A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer | Recruiting | USA | FRA | 1 |